((2S,3S)-3-methylpyrrolidin-2-yl)methanol hydrochloride | 817554-71-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: ((2S,3S)-3-methylpyrrolidin-2-yl)methanol hydrochloride
• 英文别名: [(2S,3S)-3-methyl-2-pyrrolidinyl]methanol hydrochloride；[(2S,3S)-3-methylpyrrolidin-2-yl]methanol;hydrochloride
• CAS: 817554-71-5
• 化学式: C₆H₁₃NO*ClH
• 分子量: 151.636
• InChiKey: LJVDCHZGALIYPV-RIHPBJNCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ((2S,3S)-3-methylpyrrolidin-2-yl)methanol hydrochloride 在 copper(l) iodide 、 三苯基膦 、 sodium hydroxide 、 偶氮二甲酸二乙酯 作用下， 以 二氯甲烷 、 异丙醇 为溶剂， 反应 3.0h， 生成 2-((2R,3S)-3-methyl-1-(4-(2-methylbenzyl)phenyl)pyrrolidin-2-yl)acetonitrile
  参考文献：
  名称：

  Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode

  摘要：

  A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic acid, a key pharmacophore for GPR40. Addition of a 4-cis-CF3 to the pyrrolidine improves the human GPR40 binding K-i and agonist efficacy. After further optimization, the discovery of a minor enantiomeric impurity with agonist activity led to the finding that enantiomers (R,R)-68 and (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand. Compound (R,R)-68 activates both G(q)-coupled intracellular Ca2+ flux and G(s)-coupled cAMP accumulation. This signaling bias results in a dual mechanism of action for compound (R,R)-68, demonstrating glucose-dependent insulin and GLP-1 secretion in vitro. In vivo, compound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge, encouraging further development of the series.

  DOI：

  10.1021/acs.jmedchem.6b01559
• 作为产物：
  描述：

  反式-3-甲基-L-脯氨酸 在 N-甲基吗啉 、 盐酸 、 sodium tetrahydroborate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 1.75h， 生成 ((2S,3S)-3-methylpyrrolidin-2-yl)methanol hydrochloride
  参考文献：
  名称：

  Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode

  摘要：

  A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic acid, a key pharmacophore for GPR40. Addition of a 4-cis-CF3 to the pyrrolidine improves the human GPR40 binding K-i and agonist efficacy. After further optimization, the discovery of a minor enantiomeric impurity with agonist activity led to the finding that enantiomers (R,R)-68 and (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand. Compound (R,R)-68 activates both G(q)-coupled intracellular Ca2+ flux and G(s)-coupled cAMP accumulation. This signaling bias results in a dual mechanism of action for compound (R,R)-68, demonstrating glucose-dependent insulin and GLP-1 secretion in vitro. In vivo, compound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge, encouraging further development of the series.

  DOI：

  10.1021/acs.jmedchem.6b01559

文献信息

• [EN] GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS<br/>[FR] COMPOSES DE QUINAZOLINE SUBSTITUES PAR GUANIDINO CONSTITUANT DES AGONISTES DE MC4-R
  申请人：CHIRON CORP

  公开号：WO2004112793A1

  公开（公告）日：2004-12-29

  A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.

  提供了一系列含有胍基的小分子化合物，能够作为MC4-R激动剂。当这些化合物被给予受试者时，它们对治疗MC4-R介导的疾病是有用的。这些化合物具有结构IA、IB和IC，其中变量的值在此定义。
• [EN] QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION<br/>[FR] COMPOSES DE QUINAZOLINONE AVEC BIOACCUMULATION REDUITE
  申请人：CHIRON CORP

  公开号：WO2005051391A1

  公开（公告）日：2005-06-09

  A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the formula IA and IB. IA and IB have the following structures where Z has the formula shown below and the rest of the variables are defined herein.

  提供了一种多种小分子，含有胍基的分子，能够作为MC4-R激动剂。当向受试者投药时，这些化合物对治疗MC4-R介导的疾病有用。这些化合物具有IA和IB的公式。IA和IB具有以下结构，其中Z具有下面所示的公式，其余变量在此定义。
• Quinazolinone compounds with reduced bioaccumulation
  申请人：Boyce S. Rustum

  公开号：US20050192297A1

  公开（公告）日：2005-09-01

  A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the formula IA and IB. IA and IB have the following structures where Z has the formula shown below and the rest of the variables are defined herein

  提供了一系列含有胍基的小分子化合物，能够作为MC4-R激动剂。当这些化合物被施用于受试者时，它们对治疗MC4-R介导的疾病有用。这些化合物的式子为IA和IB。IA和IB具有以下结构，其中Z的式子如下所示，其余变量在此定义。
• Substituted quinazolinone compounds
  申请人：Boyce S. Rustum

  公开号：US20050059662A1

  公开（公告）日：2005-03-17

  A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.

  提供了一系列含有胍基分子的小分子化合物，能够作为MC4-R激动剂。当这些化合物被用于治疗MC4-R介导的疾病时，它们对受体具有治疗作用。这些化合物具有结构IA、IB和IC，其中变量的值在此定义。
• SUBSTITUTED QUINAZOLINONE COMPOUNDS
  申请人：BOYCE Rustum S.

  公开号：US20100105654A1

  公开（公告）日：2010-04-29

  A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structures VA, VB, VIIA and VIIB where the values of the variables are defined herein.

  提供了一种包含鸟氨酸的小分子化合物，能够作为MC4-R激动剂。当向受试者施用这些化合物时，它们可用于治疗MC4-R介导的疾病。这些化合物具有VA、VB、VIIA和VIIB的结构，其中变量的值在此定义。